SCHEMBL700366

SCHEMBL700366

CSc1cccc(C)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.44
ATM Q13315 1/20 0.44
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 2/20 0.40
HTR1A P08908 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
HTR3A P46098 2/20 0.40
CYP2A6 P11509 1/20 0.39
TSHR P16473 2/20 0.38
ACHE P22303 1/20 0.38
ALDH1A1 P00352 3/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
MAPT P10636 4/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 2/20 0.37
NOTUM Q6P988 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30367649 1.00 TRPA1 (0.44) TRPA1ATMCYP1A2CYP3A4HTR1A
SCHEMBL3014828 0.86 ALDH1A1 (0.40) CYP3A4TSHRACHEALDH1A1MAPT
Ammonia Solution, Strong SCHEMBL7190297 0.83 ALDH1A1 (0.39) CYP3A4TSHRACHEALDH1A1MAPT
SCHEMBL29589002 0.81 HTR1A (0.53) TRPA1ATMCYP1A2CYP3A4HTR1A
SCHEMBL576045 0.81 HTR1A (0.53) TRPA1ATMCYP1A2CYP3A4HTR1A
SCHEMBL29687933 0.81 HTR1A (0.53) TRPA1ATMCYP1A2CYP3A4HTR1A
SCHEMBL576522 0.81 TRPA1 (0.46) TRPA1ATMCYP1A2CYP3A4HTR1A
SCHEMBL29722887 0.78
SCHEMBL407202 0.78
SCHEMBL2320126 0.77 CYP2A6 (0.38) TRPA1ATMCYP1A2CYP2A6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116947716-A Preparation method of 2, 3-dimethyl-4-methylsulfonyl methyl benzoate 绍兴贝斯美化工股份有限公司 2023-10-27 CN claimed
CN-116947775-A Preparation method of 3- (4, 5-dihydro-3-isoxazolyl) -2-methyl-4-methylsulfonyl methyl benzoate 绍兴贝斯美化工股份有限公司 2023-10-27 CN claimed
CN-115970605-A Device and method for continuously preparing 2,3-dimethyl phenyl sulfide 沈阳化工研究院有限公司 2023-04-18 CN claimed
CN-114088862-A Analysis method for content of 2, 3-dimethyl sulfide 京博农化科技有限公司 2022-02-25 CN claimed
CN-118146125-A Method for synthesizing topramezone intermediate 2, 3-dimethyl sulfide by copper catalysis 江苏中旗科技股份有限公司 2024-06-07 CN disclosed
CN-116947716-A Preparation method of 2, 3-dimethyl-4-methylsulfonyl methyl benzoate 绍兴贝斯美化工股份有限公司 2023-10-27 CN disclosed
CN-116947775-A Preparation method of 3- (4, 5-dihydro-3-isoxazolyl) -2-methyl-4-methylsulfonyl methyl benzoate 绍兴贝斯美化工股份有限公司 2023-10-27 CN disclosed
US-11787813-B2 Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors KSQ Therapeutics, Inc. (US) 2023-10-17 US disclosed
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-20230203046-A1 SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-06-29 US disclosed
CN-115970605-A Device and method for continuously preparing 2,3-dimethyl phenyl sulfide 沈阳化工研究院有限公司 2023-04-18 CN disclosed
EP-4023294-A1 ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE Cognition Therapeutics, Inc. (US) 2022-07-06 EP disclosed
US-6469176-B1 CROP PROTECTION COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 2002-10-22 US disclosed
US-20020032230-A1 Novel compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LTD. 2002-03-14 US disclosed
WO-2001090097-A2 NOVEL COMPOUNDS HAVING ANTIINFLAMMATORY ACTIVITY: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S RESEARCH FOUNDATION (IN) 2001-11-29 WO disclosed
EP-1129082-A1 METHOD AND NOVEL INTERMEDIATE PRODUCTS FOR PRODUCING ISOXAZOLIN-3-YL-ACYLBENZENES BASF AKTIENGESELLSCHAFT (DE) 2001-09-05 EP disclosed
CN-1300284-A Preparation of isoxazolin-3-yl-acylbenzenes BASF AG (DE) 2001-06-20 CN disclosed
EP-1077955-A1 METHOD FOR PRODUCING ISOXAZOLINE-3-YL-ACYL BENZENE BASF AKTIENGESELLSCHAFT (DE) 2001-02-28 EP disclosed
WO-2000029394-A1 METHOD AND NOVEL INTERMEDIATE PRODUCTS FOR PRODUCING ISOXAZOLIN-3-YL-ACYLBENZENES BASF AKTIENGESELLSCHAFT (DE) 2000-05-25 WO disclosed
WO-1999058509-A1 METHOD FOR PRODUCING ISOXAZOLINE-3-YL-ACYL BENZENE BASF AKTIENGESELLSCHAFT (DE) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787813-B2 Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors USP1, UPP1, USP2 TRPA1 4618/4885ATM 1260/4885CYP1A2 942/4885
US-11691947-B2 Isoindoline compositions and methods for treating neurodegenerative disease TMEM97, SLC18A2, PSD TRPA1 2680/4885ATM 2769/4885CYP1A2 3107/4885
US-20020032230-A1 Novel compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPSAB1, ACE TRPA1 2923/4885ATM 4301/4885CYP1A2 1528/4885
US-20230203046-A1 SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS USP1, UPP1, USP2 TRPA1 4618/4885ATM 1260/4885CYP1A2 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.